Clinical Conversations by Experts View all

Genomic Classifier in Prostate Cancer: High-Risk

Featured Videos

Latest Videos

Beyond Androgen Blockade - Exploring New Pathways for Treating mCRPC and mHSPC

APCCC 2024

Recent Physician-Scientist Review Articles

  State of the Evidence Review Articles
View all mHSPC Center of Excellence
PSMA-Targeted Therapy
View all PSMA-Targeted Therapy

Transformative Evidence

  Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information


Serum tumor markers can be a blessing and a curse. After definitive local therapy for prostate cancer, prostate-specific antigen (PSA) is quite sensitive and specific, and can detect micrometastatic disease well before any radiographic or symptomatic evidence of disease. When biochemical recurrence (BCR) occurs, early detection can guide curative-intent salvage therapies such as salvage radiation.


In the ARASENS trial (NCT02799602), darolutamide in combination with androgen-deprivation therapy (ADT) and docetaxel significantly reduced the risk of death by 32.5% (HR, 0.68; 95% CI, 0.57-0.80; P < .0001) compared with placebo plus ADT with docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC). We present efficacy and safety of darolutamide versus placebo in Black patients from ARASENS.

Trials in Progress

  Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information

Pivot-006 Trial

– Final positive CORE-001 safety and efficacy findings were published simultaneously online by Nature Medicine and featured at ASCO 2024 –
– 54% complete response (CR) rate in the intention-to-treat population at 24-month landmark and meets primary endpoint of the phase 2 study


  • First patient safely dosed in the pivotal Phase III 64Cu-SAR-bisPSMA diagnostic trial, CLARIFY.
  • The aim of the CLARIFY trial is to detect regional nodal metastases in participants with prostate cancer prior to radical prostatectomy.
  • Final results from the CLARIFY trial are intended to provide sufficient evidence to support an application to the FDA for the approval of the 64Cu-SAR-bisPSMA product in pre-prostatectomy patients.